You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The decision was made after Geisinger researchers and clinicians presented the health plan with evidence of the clinical utility of exome sequencing.
The in-network contracts provide coverage for insured patients in Connecticut, Maine, and New Hampshire for both high- and average-risk pregnancies.
Exact Sciences' CEO recently discussed the added coverage on a call with analysts to discuss Exact's Q4 earnings.
The company said the agreement will make its cancer diagnostics and genomic tests available to more than 2.6 million people.
NantHealth is also planning to launch a 20,000-patient multi-arm, multi-drug trial based on profiling patients' tumors with its GPS Cancer test.
The coverage is for Paradigm's PCDx test, and will extend to all patients insured by UnitedHealthcare throughout the United States.
Under the agreement, members of the health plan will have covered access to Biocept's growing menu of circulating tumor cell and circulating tumor DNA tests.
The year in personalized medicine started at the White House and ended with a congressional hearing, capturing the enthusiasm and barriers in the field.
Under a national agreement, UnitedHealthcare will cover the FoundationOne genomic profiling assay in patients with metastatic stage IV non-small cell lung cancer.
The ob-gyn groups issued a statement warning that insurers' prior authorization requirements will hinder patients' access to much needed care.
The Newsroom reports New Zealand is using genomics to trace the origins of its new coronavirus outbreak.
The Wall Street Journal reports on the struggle to meet the demand for rapid COVID-19 testing.
In Nature this week: researchers in Canada sequence the genome of the black mustard plant Brassica nigra, and more.
According to Bloomberg, Moderna has a $1.5 billion vaccine deal with the US to provide 100 million doses.